1. Home
  2. DMRA vs ANAB Comparison

DMRA vs ANAB Comparison

Compare DMRA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Damora Therapeutics Inc. Common Stock

DMRA

Damora Therapeutics Inc. Common Stock

SELL

Current Price

$22.10

Market Cap

1.4B

Sector

Health Care

ML Signal

SELL

Logo AnaptysBio Inc.

ANAB

AnaptysBio Inc.

SELL

Current Price

$45.15

Market Cap

1.4B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
DMRA
ANAB
Founded
2011
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
DMRA
ANAB
Price
$22.10
$45.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
8
Target Price
$46.78
★ $87.25
AVG Volume (30 Days)
★ 478.7K
368.2K
Earning Date
11-04-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 121.48
91.02
EPS
N/A
★ 0.11
Revenue
N/A
★ $234,603,000.00
Revenue This Year
N/A
$28.82
Revenue Next Year
N/A
$24.35
P/E Ratio
★ N/A
$416.09
Revenue Growth
N/A
★ 157.01
52 Week Low
$16.50
$33.10
52 Week High
$34.89
$73.30

Technical Indicators

Market Signals
Indicator
DMRA
ANAB
Relative Strength Index (RSI) 49.17 39.87
Support Level $18.03 $44.25
Resistance Level $22.27 $57.55
Average True Range (ATR) 1.83 1.79
MACD 0.03 -0.09
Stochastic Oscillator 30.13 9.95

Price Performance

Historical Comparison
DMRA
ANAB

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: